METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY

• 收藏
• 分享

专利权人:

INC.;SUNESIS PHARMACEUTICALS

发明人:

HAWTIN, RACHAEL, E

申请号：

NZ59482910

公开号：

NZ594829A

申请日:

2010.03.01

申请国别(地区):

NZ

年份:

2013

代理人:

摘要：

NZ 594829 Disclosed is the use of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in the manufacture of a composition for treating cancer in a subject having a BRCA2 mutation that impairs BRCA2 activity, wherein the composition is for administration of a dose of about 10-100 mg/m2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/